Cough Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Cough can occur with many signs and symptoms which include stuffy nose, hoarseness, wheezing and shortness of breath, and heartburn or a sour taste in the mouth. The treatment for cough entails antihistamines, decongestants, antibiotics, and cough suppressants.
The Cough pipeline market research report provides an overview of the Cough pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cough and features dormant and discontinued projects.
Cough Pipeline Drugs Market by Key Targets
Some of the key targets of the Cough pipeline drugs market are P2X Purinoceptor 3), Glutamate Receptor Ionotropic NMDA 1, Glutamate Receptor Ionotropic NMDA 2B, Mu Type Opioid Receptor, Sodium Channel, Bifunctional Epoxide Hydrolase 2, Kappa Type Opioid Receptor, P2X Purinoceptor 4), Sodium Channel Protein Type 10 Subunit Alpha, and Sodium Channel Protein Type 9 Subunit Alpha.
Cough Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Cough Pipeline Drugs Market
Some of the key mechanisms of action of the Cough pipeline drugs market are P2X Purinoceptor 3 Antagonist, Glutamate Receptor Ionotropic NMDA 1 Antagonist, Glutamate Receptor Ionotropic NMDA 2B Antagonist, Sodium Channel Blocker, Bifunctional Epoxide Hydrolase 2 Inhibitor, Kappa Type Opioid Receptor Agonist, Mu Type Opioid Receptor Agonist, Mu Type Opioid Receptor Antagonist, P2X Purinoceptor 4 Antagonist, and Sodium Channel Protein Type 10 Subunit Alpha Blocker.
Cough Pipeline Drugs Market, by Mechanisms of Action
For more mechanisms of action insights, download a free report sample
Key Routes of Administration in the Cough Pipeline Drugs Market
The routes of administration in the Cough pipeline drugs market are oral, inhalational, intravenous, and topical.
Cough Pipeline Drugs Market, by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Cough Pipeline Drugs Market
The molecule types in the Cough pipeline drugs market are small molecule and peptide. Small Molecule has the highest pipeline products.
Cough Pipeline Drugs Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Cough Pipeline Drugs Market Companies
Some of the key companies in the Cough pipeline drugs market are Merck & Co Inc, Tris Pharma Inc, Wuhan LL Science and Technology Development Co Ltd, Adare Pharma Solutions, Algernon Pharmaceuticals Inc, Korea United Pharm Inc, Nocion Therapeutics Inc, SiteOne Therapeutics Inc, AfaSci Inc, and Aldeyra Therapeutics Inc.
Cough Pipeline Drugs Market, by Key Companies
To know more about key companies, download a free report sample
Market Report Overview
Key Targets | P2X Purinoceptor 3), Glutamate Receptor Ionotropic NMDA 1, Glutamate Receptor Ionotropic NMDA 2B, Mu Type Opioid Receptor, Sodium Channel, Bifunctional Epoxide Hydrolase 2, Kappa Type Opioid Receptor, P2X Purinoceptor 4), Sodium Channel Protein Type 10 Subunit Alpha, and Sodium Channel Protein Type 9 Subunit Alpha |
Key Mechanisms of Action | P2X Purinoceptor 3 Antagonist, Glutamate Receptor Ionotropic NMDA 1 Antagonist, Glutamate Receptor Ionotropic NMDA 2B Antagonist, Sodium Channel Blocker, Bifunctional Epoxide Hydrolase 2 Inhibitor, Kappa Type Opioid Receptor Agonist, Mu Type Opioid Receptor Agonist, Mu Type Opioid Receptor Antagonist, P2X Purinoceptor 4 Antagonist, and Sodium Channel Protein Type 10 Subunit Alpha Blocker |
Key Routes of Administration | Oral, Inhalational, Intravenous, and Topical |
Key Molecule Types | Small Molecule and Peptide |
Key Companies | Merck & Co Inc, Tris Pharma Inc, Wuhan LL Science and Technology Development Co Ltd, Adare Pharma Solutions, Algernon Pharmaceuticals Inc, Korea United Pharm Inc, Nocion Therapeutics Inc, SiteOne Therapeutics Inc, AfaSci Inc, and Aldeyra Therapeutics Inc |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Cough (Respiratory).
- Reviews of pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects.
- Evaluation of Cough (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to pipeline therapeutics for Cough (Respiratory).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cough (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cough (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
AfaSci Inc
Aldeyra Therapeutics Inc
Algernon Pharmaceuticals Inc
Antheia Inc
Asana BioSciences LLC
Axalbion SA
Beijing Tide Pharmaceutical Co Ltd
BELLUS Health Inc
Charleston Laboratories Inc
Chiesi Farmaceutici SpA
Conrig Pharma ApS
Evotec SE
Future Analgesics
Grunenthal GmbH
Hyundai Pharma Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Korea United Pharm Inc
Merck & Co Inc
NeRRe Therapeutics Ltd
Nippon Chemiphar Co Ltd
Nocion Therapeutics Inc
Nuformix Plc
PhytoHealth Corp
Shionogi & Co Ltd
Sino Biopharmaceutical Ltd
SiteOne Therapeutics Inc
SolAeroMed Inc
Trevi Therapeutics Inc
Tris Pharma Inc
Whan In Pharm Co Ltd
Wuhan LL Science and Technology Development Co Ltd
Table of Contents
Frequently asked questions
-
What are the key targets of the Cough pipeline drugs market?
Some of the key targets of the Cough pipeline drugs market are P2X Purinoceptor 3), Glutamate Receptor Ionotropic NMDA 1, Glutamate Receptor Ionotropic NMDA 2B, Mu Type Opioid Receptor, Sodium Channel, Bifunctional Epoxide Hydrolase 2, Kappa Type Opioid Receptor, P2X Purinoceptor 4), Sodium Channel Protein Type 10 Subunit Alpha, and Sodium Channel Protein Type 9 Subunit Alpha.
-
What are the key mechanisms of action of the Cough pipeline drugs market?
Some of the mechanisms of action of the Cough pipeline drugs market are P2X Purinoceptor 3 Antagonist, Glutamate Receptor Ionotropic NMDA 1 Antagonist, Glutamate Receptor Ionotropic NMDA 2B Antagonist, Sodium Channel Blocker, Bifunctional Epoxide Hydrolase 2 Inhibitor, Kappa Type Opioid Receptor Agonist, Mu Type Opioid Receptor Agonist, Mu Type Opioid Receptor Antagonist, P2X Purinoceptor 4 Antagonist, and Sodium Channel Protein Type 10 Subunit Alpha Blocker.
-
What are the routes of administration in the Cough pipeline drugs market?
The routes of administration in the Cough pipeline drugs market are oral, inhalational, intravenous, and topical.
-
What are the molecule types in the Cough pipeline drugs market?
The molecule types in the Cough pipeline drugs market are small molecule and peptide.
-
Which are the key companies in the Cough pipeline drugs market?
Some of the key companies in the Cough pipeline drugs market are Merck & Co Inc, Tris Pharma Inc, Wuhan LL Science and Technology Development Co Ltd, Adare Pharma Solutions, Algernon Pharmaceuticals Inc, Korea United Pharm Inc, Nocion Therapeutics Inc, SiteOne Therapeutics Inc, AfaSci Inc, and Aldeyra Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Respiratory reports

